Source:http://linkedlifedata.com/resource/pubmed/id/10438363
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1999-9-23
|
| pubmed:abstractText |
Detergent-treated group B Neisseria meningitidis outer membrane vesicles (D-OMVs) from wild-type M986 and from nonencapsulated mutant M986-non-capsule variant (NCV) were compared as immunogens. Eight weeks after 3 consecutive immunizations with the immunogens, mice were challenged with a lethal dose of purified endotoxin or heat-killed or living N. meningitidis, plus d-galactosamine (400 mg/kg). D-OMVs from M986 induced bactericidal antibodies to both M986 (B : 2a : P1.5,2 : L3,7) and 6275 (B : 2a : P1.2,5 : L3) and protected the animals against both strains, whereas D-OMVs from M986-NCV did not protect the animals against infection with 6275 even when high serum bactericidal activity was induced. Tumor necrosis factor-alpha detected after bacterial infection was high in both protected and unprotected mice; interleukin (IL)-6 was high in mice that died but low in animals that survived. Exogenous administration of recombinant mouse IL-6 reversed the immunogens' protective effects. Protection against infection in mice does not necessarily correlate with the measured levels of serum bactericidal antibody alone, opsonic antibody alone, or cytokine profile alone. A comprehensive assessment of the preclinical efficacy of group B outer-membrane protein vaccines should include monitoring humoral antibodies, cytokine response, and protective effects against lethal infection.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Outer Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/lipid-linked oligosaccharides
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0022-1899
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
180
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
747-54
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10438363-Animals,
pubmed-meshheading:10438363-Bacterial Outer Membrane Proteins,
pubmed-meshheading:10438363-Bacterial Vaccines,
pubmed-meshheading:10438363-Cytokines,
pubmed-meshheading:10438363-Female,
pubmed-meshheading:10438363-Humans,
pubmed-meshheading:10438363-Immunization Schedule,
pubmed-meshheading:10438363-Lipopolysaccharides,
pubmed-meshheading:10438363-Meningococcal Infections,
pubmed-meshheading:10438363-Mice,
pubmed-meshheading:10438363-Mice, Inbred C57BL,
pubmed-meshheading:10438363-Mice, Inbred Strains,
pubmed-meshheading:10438363-Neisseria meningitidis,
pubmed-meshheading:10438363-Neutrophils,
pubmed-meshheading:10438363-Phagocytosis,
pubmed-meshheading:10438363-Serotyping,
pubmed-meshheading:10438363-Shock, Septic,
pubmed-meshheading:10438363-Species Specificity,
pubmed-meshheading:10438363-Survival Rate
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
|
| pubmed:affiliation |
Division of Bacterial Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. earth9@straubing.baynet.de
|
| pubmed:publicationType |
Journal Article
|